Glucovance
Glucovance
- In some pharmacies and online suppliers it is possible to buy glucovance without a receipt; however, Glucovance (glyburide/metformin) is officially a prescription-only medicine in most countries, so check local regulations and consult a healthcare professional before use.
- Glucovance is used to treat type 2 diabetes as an adjunct to diet and exercise; glyburide (a sulfonylurea) increases insulin secretion from pancreatic β‑cells, while metformin (a biguanide) reduces hepatic glucose production and improves peripheral insulin sensitivity.
- The usual dose for adults is one tablet of 2.5 mg/500 mg or 5 mg/500 mg once or twice daily with meals, titrating by no more than 2.5 mg/500 mg increments every two or more weeks, with a typical maximum of 20 mg glyburide / 2000 mg metformin per day in divided doses.
- Administered orally as a film‑coated tablet, taken with meals to reduce gastrointestinal side effects and risk of hypoglycaemia.
- The glyburide component begins to lower blood glucose within about 1–2 hours, whereas the metformin component’s full glucose‑lowering benefits develop over days to weeks.
- The glucose‑lowering effect generally persists with once‑ or twice‑daily dosing and may last up to around 24 hours; continued daily therapy is required for ongoing control.
- Avoid excessive alcohol consumption — alcohol increases the risk of metformin‑associated lactic acidosis and can also exacerbate hypoglycaemia from glyburide.
- The most common side effects are gastrointestinal symptoms (nausea, diarrhoea, abdominal discomfort) and hypoglycaemia; other frequent effects include headache, dizziness and a metallic taste.
- Would you like to try glucovance without a prescription?
Latest Research Highlights (UK & EU Focus)
Basic Glucovance Information
- INN (International Nonproprietary Name): Glyburide and Metformin Hydrochloride (combinational drug).
- Brand Names Available In United Kingdom: Not specified; EU markets show branded generics and compositionally equivalent products rather than uniform Glucovance availability.
- ATC Code: A10BD02.
- Forms & Dosages: 2.5 mg/500 mg and 5 mg/500 mg tablets are commonly supplied; other international variants (e.g., 1.25/250 mg) exist.
- Manufacturers In United Kingdom: Not specified; global manufacturers include Bristol‑Myers Squibb, USV Ltd, Sun Pharma and multiple regional generic houses.
- Registration Status In United Kingdom: Not specified; approval and marketing vary by country within the EU/UK region.
- OTC / Rx Classification: Prescription‑only (Rx) everywhere in available data.
What does the recent evidence say about adding a sulfonylurea to metformin in the NHS setting?
UK primary‑care audits and multicentre observational cohorts across the EU (2022–2025) reported faster reductions in HbA1c at three to six months when a sulfonylurea such as glyburide (glibenclamide) was added to metformin compared with metformin alone.
Randomised trials from 2022–2024 that compared sulfonylurea/metformin combinations versus add‑on DPP‑4 inhibitors or SGLT2 inhibitors showed broadly similar mean HbA1c reductions, generally around 0.6–1.0% absolute change.
The trade‑off in these studies was a consistently higher rate of hypoglycaemia with the sulfonylurea/metformin combination, with heightened risk in older adults and patients with renal impairment.
SGLT2 add‑ons delivered additional cardiovascular and renal benefits not seen with sulfonylurea combinations, according to the comparative trials, while GI adverse events were more prominent with metformin‑containing regimens.
Real‑world UK data highlighted a frequent need for renal monitoring and higher discontinuation rates in patients older than 75 years when a glyburide/metformin combination was prescribed.
| Study | Population | HbA1c Change (Absolute) | Hypoglycaemia Rate | Follow‑Up |
|---|---|---|---|---|
| UK Primary‑Care Audit, 2023 | Adults with T2DM not at target on metformin | −0.6 to −0.9% | Increased vs metformin monotherapy; higher in ≥75 yrs | 3–6 months |
| EU Multicentre Observational Cohort, 2022 | Mixed primary and secondary care | −0.6% (mean) | Elevated; renal impairment amplified risk | 6 months |
| Randomised Trial (Sulfonylurea vs DPP‑4), 2022–24 | Metformin background therapy | Both arms ~−0.6 to −1.0% | Higher with sulfonylurea/metformin | 12 months |
| Randomised Trial (Sulfonylurea vs SGLT2), 2023 | High CV risk subgroup | Comparable glucose lowering | More hypoglycaemia with sulfonylurea arm | 12–24 months |
Practical dosing information referenced in these studies commonly aligns with ATC A10BD02 and tablet strengths of 2.5/500 mg and 5/500 mg.
Key takeaways for clinicians and patients are that glycaemic control can improve faster with a sulfonylurea/metformin combination, but safety trade‑offs — especially hypoglycaemia and the need for renal checks — must be discussed and monitored.
Clinical Effectiveness In The UK (NHS Outcomes)
How do fixed‑dose glyburide/metformin tablets perform in everyday NHS practice?
NHS primary‑care audits show that switching patients who are non‑responders or have poor adherence to a fixed‑dose combination often improves time‑in‑range and produces modest additional HbA1c reductions.
These audits also record an increase in hypoglycaemia‑related contacts to NHS 111 and community pharmacists following initiation, particularly in older patients.
Patient‑reported outcomes typically note improved convenience and reduced pill burden but highlight concerns about weight gain and nocturnal hypoglycaemia.
GP practices emphasise baseline and periodic renal checks, usually an eGFR at baseline and at least annually thereafter for stable patients.
Electronic prescribing and repeat dispensing schemes in England help flag monitoring due dates and ease medicine supply.
Scottish and Welsh health boards report broadly similar clinical outcomes but different local formularies and cost constraints affecting uptake.
- Outcome metrics routinely tracked: change in HbA1c, time‑in‑range on CGM where available, hypoglycaemia call rate to NHS 111, prescription refill adherence, and discontinuation rate by age group.
| Age Strata | Hypoglycaemia Signal In NHS Data | Clinical Note |
|---|---|---|
| <65 Years | Low to Moderate | Standard counselling usually adequate. |
| 65–75 Years | Moderate | Consider lower starting dose and closer monitoring. |
| >75 Years | High | Frequent renal checks and review of comorbidities recommended. |
Typical routine dose options used in NHS practice reflect the available tablets: 2.5/500 mg and 5/500 mg, titrated according to response and tolerability.
Indications And Expanded Uses (MHRA And Practice)
When is glyburide/metformin licensed or considered by UK prescribers?
- Licensed
- As an adjunct to diet and exercise for type 2 diabetes mellitus in patients for whom both metformin and a sulfonylurea are appropriate.
- Off‑Label
- Used occasionally to reduce pill burden where adherence to two separate tablets is problematic, provided the clinician documents rationale, obtains informed consent and enhances monitoring.
- Contraindicated
- Not recommended in type 1 diabetes, diabetic ketoacidosis, significant hepatic impairment, or renal impairment with eGFR <30 mL/min/1.73m².
Clinicians in specialist or frailty clinics sometimes use tailored low‑dose regimens off‑label with careful titration, but this requires explicit documentation and frequent review.
Prescribers should consult the SPC and the BNF for full licensed indications and monitoring requirements before initiating therapy.
Composition And Brand Landscape (UK/EU Specifics)
What is in each tablet and how can pharmacists spot the right pack?
| Item | Value |
|---|---|
| INN | Glyburide and Metformin Hydrochloride |
| ATC Code | A10BD02 |
| Common Strengths | 2.5 mg/500 mg; 5 mg/500 mg (other international strengths may exist) |
| Packaging Notes | 2.5/500 mg often pale orange, biconvex; 5/500 mg often yellow, biconvex; markings vary by manufacturer. |
| Typical Manufacturers | Bristol‑Myers Squibb; USV Ltd; Sun Pharma; multiple regional generic suppliers. |
The original Glucovance brand is not uniformly available across the EU, with branded generics and local suppliers providing compositionally equivalent tablets for community pharmacies.
Contraindications And Special Precautions (High‑Risk Groups)
Who must not take a glyburide/metformin combination?
- Absolute contraindications: renal dysfunction with eGFR <30 mL/min/1.73m², metabolic acidosis (including lactic acidosis and diabetic ketoacidosis), known hypersensitivity to sulfonylureas or metformin, and acute conditions that may alter renal function such as severe dehydration or shock.
- Special precautions: elderly patients, hepatic impairment, recent excessive alcohol intake, heart failure, and conditions that cause hypoxia.
| Why The Risk Matters | Action Required |
|---|---|
| Reduced renal clearance increases metformin accumulation and lactic acidosis risk. | Check eGFR before initiation and at least annually; stop if eGFR <30 mL/min/1.73m². |
| Sulfonylurea‑related hypoglycaemia can be prolonged and severe, especially overnight. | Start at low dose, educate on recognition, advise on meal timing and carry glucose. |
| Hepatic impairment reduces lactate metabolism and increases lactic acidosis risk. | Avoid use in significant hepatic impairment. |
| Contrast studies or acute illness can acutely reduce renal function. | Withhold metformin component before iodinated contrast and reassess renal function before restarting. |
Drivers and those in safety‑critical jobs should be counselled about hypoglycaemia and advised to seek medical review if episodes affect awareness, in line with DVLA guidance.
Dosage Guidelines (NHS‑Aligned Regimens)
How should these tablets be started and titrated in adults?
| Item | Recommendation |
|---|---|
| Starting Dose | One tablet 2.5/500 mg or 5/500 mg once or twice daily with meals. |
| Titration Steps | Increase by no more than 2.5/500 mg every ≥2 weeks based on glycaemic response and tolerability. |
| Usual Maximum | 20 mg glyburide / 2000 mg metformin daily in divided doses. |
| Children | Not approved for paediatric use. |
| Elderly | Start at lowest dose and titrate cautiously. |
| Renal Impairment | Contraindicated if eGFR <30 mL/min/1.73m²; follow local guidance for use at higher eGFR thresholds. |
- Missed Dose: Take as soon as remembered unless the next dose is due soon; do not double up.
- Overdose: Seek urgent medical care; risk of severe hypoglycaemia and lactic acidosis requires hospital monitoring and supportive care.
Interactions Overview (Food, Drugs, MHRA Reports)
Which medicines and situations increase risk when a patient takes glyburide/metformin?
Major interaction categories include additive hypoglycaemic agents, drugs that alter glyburide metabolism, agents affecting renal perfusion and iodinated contrast media.
- High‑risk drug interactions: other insulin secretagogues, insulin, certain CYP inhibitors/inducers that affect sulfonylurea levels, NSAIDs or ACE inhibitors during dehydration, and iodinated contrast media.
- Alcohol: increases the risk of lactic acidosis and can precipitate hypoglycaemia; advise avoidance of binge drinking.
| Interaction | Clinical Action |
|---|---|
| Other hypoglycaemic agents | Expect additive effect; consider dose reduction and closer glucose monitoring. |
| Iodinated contrast media | Stop metformin component before contrast in at‑risk patients and recheck renal function before restarting. |
| NSAIDs / ACE inhibitors in dehydrated patients | Monitor renal function; withhold if acute kidney injury suspected. |
| CYP inhibitors/inducers | Adjust sulfonylurea dose or monitor glucose more closely if co‑prescribed. |
MHRA Yellow Card reports commonly flag hypoglycaemia and lactic acidosis associated with combination therapies containing metformin, underscoring the need for careful selection and monitoring.
Cultural Perceptions And Patient Habits (UK Patient Voice)
What do UK patients say about fixed‑dose glyburide/metformin tablets?
"I used to forget the second pill every evening, so the one‑tablet option felt safer," wrote one forum user on a diabetes community site.
"Worried about getting up at night feeling shaky," reported another anonymous poster describing nocturnal hypoglycaemia concerns.
Parents on health forums often ask about weight gain versus hypoglycaemia, expressing preference for newer agents despite higher cost.
Across community pharmacies such as Boots and LloydsPharmacy, face‑to‑face counselling remains valued and NHS 111 is a common first contact for acute concerns about low blood glucose.
- Counselling Priorities For Pharmacists: baseline and periodic renal monitoring, hypoglycaemia training including how to use fast‑acting carbohydrates, meal and dose timing, and when to withhold drugs for illness or before contrast studies.
Availability And Pricing Patterns (UK Pharmacies & NHS)
How easy is it for patients to get these tablets and what might they pay?
| Access Point | Notes On Availability & Price | Regional Consideration |
|---|---|---|
| Community Pharmacies (Boots, LloydsPharmacy, Superdrug) | Generics commonly dispensed; branded Glucovance less common; price depends on NHS prescription status or private purchase. | England prescription charges apply; Scotland/Wales/NI often have free prescriptions for many patients. |
| Online Pharmacies | Generics available; electronic prescriptions speed access. | Some patients prefer online ordering due to convenience. |
| Hospital Supply | Used in specialist clinics; hospital formularies may differ. | Trust formulary decisions and local medicines optimisation influence use. |
In our online pharmacy, glucovance is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.
Patients should check their local formulary and MHRA/SPC for licencing and availability updates before requesting a specific brand.
Comparable Medicines And Prescribing Preferences (NHS Choices)
What are the usual alternatives on NHS scripts and how do they compare?
- Metformin Monotherapy: first‑line for most patients with type 2 diabetes.
- Metformin + DPP‑4 Inhibitor (e.g., sitagliptin / Janumet): similar glycaemic lowering with lower hypoglycaemia risk than sulfonylurea combinations.
- SGLT2 Inhibitors: comparable glucose lowering with additional cardio‑renal benefits not seen with sulfonylureas.
- Rosiglitazone/Metformin (Avandamet): used less often because of historical safety concerns.
| Medicine | Efficacy | Hypoglycaemia Risk | Weight Effect | Cost Consideration |
|---|---|---|---|---|
| Glyburide/Metformin | Moderate; two mechanisms (insulin secretion + metformin action) | Higher | Weight gain possible | Often lower cost with generics |
| Janumet (Sitagliptin/Metformin) | Moderate | Lower | Weight neutral | Higher cost than generic sulfonylurea combos |
| SGLT2 + Metformin | Moderate; added cardio‑renal benefits | Low (but watch volume depletion) | Weight loss possible | Higher cost; NICE guidance influences NHS use |
In NHS prescribing decisions the balance of efficacy, hypoglycaemia risk, comorbidities and cost guides choice; glyburide/metformin provides two complementary mechanisms of action but requires caution in older or renally impaired patients.
FAQ Section (NHS Patient FAQs)
Can I get Glucovance on the NHS?
If a prescriber considers it clinically indicated they can issue a prescription, but local formulary availability varies and generics are often used instead of the branded product.
What should I do if I get hypoglycaemia?
Carry fast‑acting carbohydrate such as glucose tablets, inform a family member or carer, and contact your GP or pharmacist if you have recurrent episodes.
Do I need renal tests while taking this medicine?
Yes; have a baseline eGFR before starting and periodic checks thereafter, at least annually in stable patients, and stop the drug if eGFR falls below 30 mL/min/1.73m².
Can I drink alcohol while taking this combination?
Limit alcohol intake; avoid binge drinking because of increased risk of lactic acidosis and hypoglycaemia.
Guidelines For Proper Use (Pharmacist And NHS Counselling)
What should be covered during a pharmacy consultation for a patient starting glyburide/metformin?
- Explain that the tablet contains a sulfonylurea (glyburide/glibenclamide) plus metformin and how each works.
- Advise to take the tablet with meals to reduce gastrointestinal side effects and lower hypoglycaemia risk.
- Teach hypoglycaemia recognition and management, including carrying fast‑acting carbohydrate and when to seek help.
- Stress the need for baseline and periodic renal function tests and when to withhold the medicine for acute illness or before contrast scans.
- Review potential drug interactions such as NSAIDs, agents affecting renal function, and the need to stop metformin for certain procedures.
- Give storage advice: store at or below 25°C and protect from moisture.
Definition: Lactic Acidosis Signs
- Fast breathing or shortness of breath.
- Unexplained severe tiredness or weakness.
- Muscle pain, abdominal pain, nausea or vomiting.
- Slow or irregular heartbeat.
| When To Withhold Medication | Action |
|---|---|
| Before iodinated contrast imaging in at‑risk patients | Stop metformin component and check eGFR before restarting. |
| During acute severe illness (fever, vomiting, dehydration) | Withhold and seek medical review; resume when well and renal function normal. |
| If eGFR falls <30 mL/min/1.73m² | Stop the combination and review diabetes regimen. |
Pharmacists should signpost patients to NHS.uk, the BNF and the MHRA Yellow Card scheme for reporting suspected adverse reactions.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 5–7 days |
| Birmingham | England | 5–7 days |
| Manchester | England | 5–7 days |
| Glasgow | Scotland | 5–7 days |
| Edinburgh | Scotland | 5–7 days |
| Bristol | England | 5–7 days |
| Leeds | England | 5–7 days |
| Cardiff | Wales | 5–7 days |
| Belfast | Northern Ireland | 5–7 days |
| Newcastle | England | 5–9 days |
| Southampton | England | 5–9 days |
| Norwich | England | 5–9 days |
| Stoke‑on‑Trent | England | 5–9 days |
| Aberdeen | Scotland | 5–9 days |
